LENZ Therapeutics Inc. (LENZ) is gearing up for a key regulatory catalyst that could prove to be a defining moment for the company.
The company's lead product candidate, LNZ100, proposed for the treatment of presbyopia, is under FDA review, with a decision expected on August 8, 2025.
Presbyopia is the age-related decline in near vision that occurs as the eye gradually loses its ability to focus on close objects, resulting in blurry near vision. About 128 million people in the U.S. are impacted by presbyopia. Currently, there are only two FDA-approved eye drop solutions for the treatment of presbyopia - AbbVie Inc.'s Vuity and Orasis Pharmaceuticals' Qlosi.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.